- Home
- TNXP vs CXE Comparison
TNXP vs CXE Comparison
Compare TNXP & CXE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNXP
- CXE
- Stock Information
- Founded
- TNXP 2007
- CXE 1989
- Country
- TNXP United States
- CXE United States
- Employees
- TNXP N/A
- CXE N/A
- Industry
- TNXP Biotechnology: Pharmaceutical Preparations
- CXE Investment Managers
- Sector
- TNXP Health Care
- CXE Finance
- Exchange
- TNXP Nasdaq
- CXE Nasdaq
- Market Cap
- TNXP 116.9M
- CXE 110.0M
- IPO Year
- TNXP N/A
- CXE N/A
- Fundamental
- Price
- TNXP $15.71
- CXE $3.49
- Analyst Decision
- TNXP Strong Buy
- CXE
- Analyst Count
- TNXP 2
- CXE 0
- Target Price
- TNXP $585.00
- CXE N/A
- AVG Volume (30 Days)
- TNXP 1.5M
- CXE 62.9K
- Earning Date
- TNXP 05-12-2025
- CXE 01-01-0001
- Dividend Yield
- TNXP N/A
- CXE 4.36%
- EPS Growth
- TNXP N/A
- CXE N/A
- EPS
- TNXP N/A
- CXE 0.07
- Revenue
- TNXP $10,094,000.00
- CXE N/A
- Revenue This Year
- TNXP $12.17
- CXE N/A
- Revenue Next Year
- TNXP $789.15
- CXE N/A
- P/E Ratio
- TNXP N/A
- CXE $51.00
- Revenue Growth
- TNXP 29.94
- CXE N/A
- 52 Week Low
- TNXP $6.76
- CXE $2.95
- 52 Week High
- TNXP $672.00
- CXE $3.67
- Technical
- Relative Strength Index (RSI)
- TNXP 44.80
- CXE 32.33
- Support Level
- TNXP $15.23
- CXE $3.44
- Resistance Level
- TNXP $22.25
- CXE $3.51
- Average True Range (ATR)
- TNXP 2.36
- CXE 0.06
- MACD
- TNXP -0.54
- CXE -0.01
- Stochastic Oscillator
- TNXP 16.54
- CXE 31.43
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
About CXE MFS High Income Municipal Trust
Mfs High Income Municipal Trust is a United States-based diversified closed-end management investment company. Its investment objective is to seek high current income exempt from federal income tax. The fund invests a majority of its net assets, including assets attributable to preferred shares and borrowings for investment purposes, in tax-exempt bonds and tax-exempt notes.